within Pharmacolibrary.Drugs.ATC.G;

model G04BX11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.0,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Collagen is a naturally occurring protein that forms the primary structural component of connective tissues in the body. Pharmaceutical or supplemental collagen preparations have been investigated or used for tissue regeneration, wound healing, cosmetic purposes, and, under the ATC code G04BX11, as a urogynecological agent for the treatment of stress urinary incontinence. As of now, collagen-based drugs are used in specific clinical settings but are not routine systemic therapeutics, and products may vary widely in formulation.</p><h4>Pharmacokinetics</h4><p>No published peer-reviewed pharmacokinetic parameters available for medicinal collagen (G04BX11) in humans, as it is a large protein often used locally (e.g., injectable bulking agent); systemic absorption and related PK properties are negligible or not studied for these therapeutics.</p><h4>References</h4><ol><li><p>Chan, ML, et al., &amp; Henshaw, J (2022). Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. <i>Clinical pharmacokinetics</i> 61(2) 263–280. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01059-1&quot;>10.1007/s40262-021-01059-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34431071/&quot;>https://pubmed.ncbi.nlm.nih.gov/34431071</a></p></li><li><p>Frost, GI (2007). Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. <i>Expert opinion on drug delivery</i> 4(4) 427–440. DOI:<a href=&quot;https://doi.org/10.1517/17425247.4.4.427&quot;>10.1517/17425247.4.4.427</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17683255/&quot;>https://pubmed.ncbi.nlm.nih.gov/17683255</a></p></li><li><p>Oyama, S, et al., &amp; Nakata, K (2022). A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. <i>Scientific reports</i> 12(1) 18102–None. DOI:<a href=&quot;https://doi.org/10.1038/s41598-022-23152-6&quot;>10.1038/s41598-022-23152-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36302840/&quot;>https://pubmed.ncbi.nlm.nih.gov/36302840</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G04BX11;
